Repligen Seeks Preliminary Injunction Against Bristol’s RA Therapy Orencia
This article was originally published in The Pink Sheet Daily
Executive Summary
Repligen says Bristol’s abatacept infringes Repligen’s patent for method of treating rheumatoid arthritis.
You may also be interested in...
Maxygen “Confident” About MAXY-4 Patents – Astellas, Too
Deal with transplant-drug firm shows faith that Repligen/BMS-like skirmish not in the cards.
Maxygen “Confident” About MAXY-4 Patents – Astellas, Too
Deal with transplant-drug firm shows faith that Repligen/BMS-like skirmish not in the cards.
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.